DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

AndroGel in Men With Major Depression and Incomplete Response to Antidepressant Treatment

Information source: Mclean Hospital
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Depressive Disorder, Major

Intervention: Testosterone gel (Drug); Placebo (Drug)

Phase: Phase 4

Status: Completed

Sponsored by: Mclean Hospital

Official(s) and/or principal investigator(s):
Harrison G Pope, M.D., Principal Investigator, Affiliation: Mclean Hospital
Stuart N Seidman, M.D., Principal Investigator, Affiliation: Columbia University


We hypothesize that AndroGel may offer some relief to subjects with low or borderline testosterone levels who suffer from depression and have failed to respond to a trial of a standard antidepressant. During this nine week, outpatient, double-blind study, male subjects between the ages of 30 and 65 years with treatment-refractory depression and low or borderline low testosterone levels will be treated with either AndroGel or placebo. Following this nine week, double-blind phase, eligible subjects will have the option to continue into a six month, open-label phase during which time all subjects will receive the AndroGel patch.

Clinical Details

Official title: A Parallel-Group, Placebo-Controlled Trial of AndroGel in Men With Major Depressive Disorder Who Display an Incomplete Response to Standard Antidepressant Treatment

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Primary outcome: 21-item Hamilton Depression Rating Scale Score (HAM-D)

Secondary outcome: Montgomery Asberg Depression Rating Scale (MADRS)

Detailed description: We will recruit 100 men between the ages of 30 and 65 years who have treatment-refractory depression and low or borderline low testosterone levels for participation in this study. For a period of nine weeks subjects will receive double-blind treatment with either AndroGel (testosterone gel) or placebo. During this double-blind treatment phase subjects will come to McLean Hospital for a total of seven visits. Both clinical assessments (including ratings of your levels of depression and anxiety, quality of life, and visuospatial memory)and laboratory tests will be performed at these visits. Following the nine week, double-blind phase, eligible subjects may enter into a six month, open-label treatment phase in which all subject receive AndroGel. If you participate in the open-label phase, you will be asked to return to the site for 8 visits during the six month period.


Minimum age: 30 Years. Maximum age: 65 Years. Gender(s): Male.


Inclusion Criteria:

- Male

- 30-65 years old

- Taking at least one serotonergic antidepressant at adequate dose for at least six

weeks but still meeting DSM-IV criteria for major depressive disorder within the past year

- HAM-D score >12

Exclusion Criteria:

- Current suicidal ideation

- Substance abuse or dependence within the past year

- Current or past psychotic symptoms

- A history of bipolar disorder

- A prostate-specific antigen (PSA) level greater than 4. 0 ng/ml

- Other clinically significant medical condition

- A history of failing to show any clinically significant response to two or more

adequate trials of different antidepressants.

Locations and Contacts

The Chaim Sheba Medical Center, Tel-Hashomer 52621, Israel

McLean Hospital, Belmont, Massachusetts 02478, United States

Additional Information

Starting date: April 2006
Last updated: November 17, 2010

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017